Rounds: Take the Money and R1, Megan Scheffel, Dan Bise, and Jeremy Friese
From Lifers with Christina Farr · 53:19
Show by Christina Farr
In Episode 5 of Rounds, Stephanie Davis and Christina Farr break down the latest healthcare headlines — including Oura's step toward an IPO with its S-1 filing revealing $1.4 billion in revenue, and a former Anthropic researcher's warning to the BBC that AI staff are "genuinely frightened" for humanity's future — before sitting down with Megan Scheffel, Head of Life Science and Healthcare at SVB, Dan Bise, Executive Vice President of Strategy & Corporate Development at R1, and Jeremy Friese, CEO and Founder of Humata Health. We'll cover: Oura's S-1 filing and what it signals about the company's path to IPO Key takeaways from SVB's Healthcare Investments and Exits report — including why fewer specialized funds (not less capital) are driving the fundraising slowdown, why deal volume hit a multiyear low even as total dollars held steady, and why investors are increasingly rewarding proven commercial viability over pure technology hype The diverging exit landscape between biopharma (a record M&A year driven by looming patent cliffs) and healthtech (strong IPO performance, but few companies actually going public) How blurring lines between Dx/Tools, device, and biopharma are reshaping where capital flows The thesis behind CD&R and TowerBrook's take-private of R1, and the company's shift from tech-enabled services to a true AI-native, technology-first approach to automating the healthcare revenue cycle R1's first two acquisitions, Phare Health and Humata Health, and how Humata's prior authorization platform fills a key gap in R1's strategy to reduce downstream payer denials Dan Bise's investment approach — from setting strategy to evaluating the competitive landscape to aligning investors and the Board — and how it mirrors a thesis-driven, PE-style playbook Jeremy Friese's perspective as Humata's founder on what set R1 apart from other potential acquirers, and what convinced him to sell Hosts and Guests: Christina Farr, CEO, Second Opinion; GP, Scrub Capital Stephanie Davis, Healthcare Industry Analyst Megan Scheffel, Head of Life Science and Healthcare at SVB Dan Bise, EVP, Strategy and Corporate Development at R1 Jeremy Friese, Founder and CEO of Humata Health Sponsored by Silicon Valley Bank.
More episodes of Lifers with Christina Farr
More episodes
- Systems of record vs. systems of action: the future of the EHR | Paul Brient, athenahealth
- Inside the Complexity of U.S. Healthcare: Kumar Shwetabh of Access Healthcare
- Baylor Scott & White redirected 55% of would-be ER cases, with CEO Pete McCanna
- Rounds: Beyond Ennoble Intentions: AI, Home Care & the New IPO Bar | ICR Healthcare, Ennoble Care
- Why simple ideas win in healthcare | Adam Pellegrini, CEO of TytoCare
- Can AI predict a patient’s future? | Dr Jay Shah, Concurrence & Dr Prakash Jayakumar, Dell Med
- A hospital AI deal done in under two months | Dr. Ilya Burkov, Nebius & Thomas Knox, VitVio
- Rounds: The Mental Health Moment
- Surviving the digital therapeutics graveyard—and thriving | David Benshoof Klein, Click Therapeutics
- Healthcare runs a 1980s model in 2026 | Aaron Miri, Baptist Health
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.